cladribine has been researched along with Acute Myelogenous Leukemia in 100 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 13 (13.00) | 18.2507 |
| 2000's | 17 (17.00) | 29.6817 |
| 2010's | 43 (43.00) | 24.3611 |
| 2020's | 27 (27.00) | 2.80 |
| Authors | Studies |
|---|---|
| Feng, SZ; Han, MZ; He, Y; Jiang, EL; Shi, YY; Zhang, GX; Zhang, RL | 1 |
| DU, JW; He, YZ; Huang, YX; Li, KX; Li, YH; Pan, WY; Song, CY; Tu, SF; Wu, HY; Zheng, YL | 1 |
| Gao, W; Hu, J; Jiang, J; Wan, M; Wang, L | 1 |
| Andreeff, M; Bhalla, KN; Borthakur, G; Daver, NG; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Issa, GC; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Malla, R; Montalban-Bravo, G; Ohanian, M; Pemmaraju, N; Popat, UR; Quagliato, K; Rausch, CR; Ravandi, F; Reville, PK; Sasaki, K; Short, NJ; Takahashi, K; Wang, X | 1 |
| Alsdorf, WH; Bokemeyer, C; Brauneck, F; Fiedler, W; Ghandili, S; Karagiannis, P; Klingler, F; Modemann, F; Wolschke, C | 1 |
| Chen, P; Wang, D; Wang, F; Xie, M; Yang, M | 1 |
| Al Jammal, M; Al-Juhaishi, T; Al-Kindi, SG; Arora, S; Badhwar, A; Chahine, N; Chami, T; Hajjari, J; Heisler, AC; Hoit, BD; Janus, SE; Mously, H | 1 |
| Bazinet, A; Borthakur, G; Chien, KS; Darbaniyan, F; Daver, NG; DiNardo, CD; Garcia-Manero, G; Hammond, D; Jabbour, EJ; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, HM; Konopleva, MY; Montalban-Bravo, G; Pemmaraju, N; Pierce, SA; Ravandi, F; Sasaki, K; Venugopal, S | 1 |
| Boeckh, M; Cheng, GS; Chung, EL; Delaney, C; Halpern, AB; Hill, JA; Huebner, EM; Kiem, ES; Kimball, LE; Leisenring, WM; Liu, C; Pergam, SA; Schonhoff, KG; Walter, RB; Walti, CS; Xie, H | 1 |
| Huang, L; Huang, W; Jin, J; Li, L; Li, M; Li, Y; Mao, X; Meng, F; Peng, Y; Tong, X; Xu, B; Zhang, D | 1 |
| Appelbaum, J; Curley, N; Estey, EH; Gooley, T; Halpern, AB; Hendrie, PC; Kopmar, NE; Lim, J; Percival, MM; Russell, K; Schonhoff, K; Scott, BL; Shaw, C; Walter, RB | 1 |
| Abkowitz, JL; Appelbaum, JS; Becker, PS; Cassaday, RD; Estey, EH; Garcia, KA; Ghiuzeli, MC; Halpern, AB; Hendrie, PC; Keel, SB; Oehler, VG; Orozco, JJ; Othus, M; Percival, MM; Rodríguez-Arbolí, E; Scott, BL; Walter, RB | 1 |
| Bataller, A; Borthakur, G; Bose, P; Champlin, R; Daver, N; DiNardo, CD; Ferrajoli, A; Garcia-Manero, G; Islam, R; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Marx, KR; Molica, M; Pemmaraju, N; Rausch, CR; Ravandi, F; Shpall, E; Tidwell, RS; Wang, S; Ylimaz, M | 1 |
| Cao, S; Dong, Y; Tao, Q; Wang, J; Zhang, Q | 1 |
| Bodzenta, E; Bolkun, L; Brzozowski, K; Czemerska, M; Giebel, S; Gromek, T; Grosicki, S; Grzybowska-Izydorczyk, O; Helbig, G; Hellman, A; Holowiecki, J; Hus, M; Kloczko, J; Knopinska-Posluszny, W; Krawczynska, A; Kuydowicz, M; Lech-Maranda, E; Nowicki, M; Patkowska, E; Piekarska, A; Pluta, A; Razny, M; Robak, T; Sobas, M; Stelmach, P; Stepka, K; Szmigielska-Kaplon, A; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wojcik, K; Wrobel, T | 1 |
| Chen, K; Jiang, H; Li, H; Shao, JB; Yang, JW; Zhang, N; Zhu, JS | 1 |
| Breccia, M; Capria, S; Foa, R; Jabbour, E; Kadia, TM; Molica, M; Trisolini, S | 1 |
| Abboud, CN; Abboud, R; Chendamarai, E; DiPersio, JF; Ghobadi, A; Pusic, I; Rettig, MP; Riedell, PA; Schroeder, MA; Stockerl-Goldstein, K; Trinkaus, KM; Uy, GL; Vij, R; Westervelt, P | 1 |
| Anžej Doma, S; Pajič, T; Sever, M; Škerget, M | 1 |
| Brossart, P; Glasmacher, A; Hahn-Ast, C; Mayer, K; Schmidt-Wolf, IGH; Schwab, K; von Lilienfeld-Toal, M | 1 |
| Becker, PS; Buckley, SA; Estey, EH; Halpern, AB; Hendrie, PC; Oehler, VG; Othus, M; Palmieri, R; Percival, MM; Scott, BL; Walter, RB | 1 |
| Basak, GW; Drozd-Sokolowska, J; Dwilewicz-Trojaczek, J; Gierej, B; Halaburda, K; Karakulska-Prystupiuk, E; Sachs, W; Tormanowska, M; Urbanowska, E; Wiktor-Jedrzejczak, W | 1 |
| Becker, PS; Godwin, CD; Halpern, AB; Othus, M; Palmieri, R; Percival, MM; Walter, RB | 1 |
| Chen, XJ; Chen, YM; Guo, Y; Liu, F; Liu, LP; Liu, TF; Liu, XM; Quan Qi, B; Ruan, M; Yang, WY; Zhang, AL; Zhang, L; Zhu, XF; Zou, Y | 1 |
| Baron, J; Cronin, TL; Elshoury, A; Freyer, CW; Griffiths, EA; Ji, W; Muppidi, MR; Ontiveros, EP; Przespolewski, A; Thompson, JE; Thota, S; Wang, ES | 1 |
| DiNardo, CD; Kadia, TM; Kantarjian, HM; Ravandi, F; Welch, MA | 1 |
| Borthakur, G; Burger, J; Daver, N; DiNardo, CD; Estrov, Z; Ferrajoli, A; Garcia-Manero, G; Huang, X; Jabbour, E; Jain, N; Kadia, TM; Kanagal-Shamanna, R; Kantarjian, H; Konopleva, M; Pemmaraju, N; Pierce, S; Popat, U; Rausch, C; Ravandi, F; Verstovsek, S; Wang, X | 1 |
| Alexander, TB; Inaba, H; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Triplett, BM; Wang, L | 1 |
| Ali, AM; Cooley, SA; DiPersio, JF; Miller, JS; Rashidi, A; Romee, R; Shanley, R; Ustun, C; Vij, KR; Weisdorf, DJ; Westervelt, P | 1 |
| Bates, J; Buhlinger, K; Deal, AM; Foster, MC; Jamieson, KJ; Muluneh, B; Van Deventer, HW; Zeidner, JF | 1 |
| Bigenzahn, JW; Choi, HS; Felberbauer, F; Gisslinger, H; Gültekin, S; Hoermann, G; Jäger, U; Jeryczynski, G; Kazianka, L; Kenner, L; Korkmaz, B; Kornauth, C; Krall, N; Kralovics, R; Kubicek, S; Lopez de la Fuente, O; Mayerhoefer, ME; Merkel, O; Miura, K; Müllauer, L; Ocko, K; Prager, GW; Prutsch, N; Ringler, A; Sabler, M; Schmolke, AS; Simonitsch-Klupp, I; Snijder, B; Sperr, WR; Staber, PB; Superti-Furga, G; Valent, P; van der Kouwe, E; Vladimer, GI | 1 |
| Evans, AG; Goorha, S; Hobbs, ALV; Leonard, JM; Mills, EL; Seligson, ND | 1 |
| Braun, JT; Fesler, MJ; Freter, CE; Lionberger, JM; Petruska, PJ; Reddy, DV; Schoen, MW; Woelich, SK | 1 |
| Dahm, AEA; Dybedal, I; Habberstad, AH; Randen, U; Spetalen, S; Tjønnfjord, GE; Tran, HTT | 1 |
| Brayer, J; Rose, A | 1 |
| Huang, Y; Liu, DD; Lv, TT; Xu, J; Yuan, GL; Zhou, XF | 1 |
| Anwar, A; Becker, PS; Buckley, SA; Cassaday, RD; Chen, TL; Estey, EH; Gardner, KM; Halpern, AB; Hendrie, PC; Huebner, EM; Oehler, VG; Orlowski, KF; Orozco, JJ; Othus, M; Percival, MM; Scott, BL; Smith, HA; Walter, RB | 1 |
| Abughanimeh, O; Bahaj, W; Foxworth, J; Gaur, R; Qasrawi, A; Qasrawi, L | 1 |
| Lv, T; Tian, X; Wang, L; Xu, J; Yuan, G | 1 |
| Kontopoulou, E; Kunz, F; Reinhardt, D; Reinhardt, K; Soldierer, M; Strachan, S; Thakur, BK | 1 |
| Hu, Y; Huang, H; Jin, A; Jin, M; Luo, Y; Tan, Y; Wei, G; Wu, W; Yang, L; Yu, J | 1 |
| Ge, Z; Han, Q; Ma, J; Song, H; Zhou, A; Zi, J | 1 |
| Bogdanovic, A; Colovic, N; Gotic, M; Kraguljac-Kurtovic, N; Marisavljevic, D | 1 |
| Campana, D; Cao, X; Crews, KR; Dolan, ME; Downing, J; Gandhi, V; Hartford, C; Lamba, JK; Mitra, AK; Plunkett, W; Pounds, S; Raimondi, S; Ribeiro, RC; Rubnitz, JE | 1 |
| Al Ali, NH; Bello, CM; Duong, VH; Fernandez, HF; Jaglal, MV; Komrokji, RS; Lancet, JE; List, AF; Padron, E | 1 |
| Robak, T; Wierzbowska, A | 1 |
| Abboud, CN; Cashen, A; Dipersio, JF; Fiala, M; McBride, A; Ramsingh, G; Stockerl-Goldstein, K; Uy, G; Vij, R; Westervelt, P | 1 |
| Cortes, JE; Feldman, EJ; Goldberg, SL; Hogge, DE; Kantarjian, H; Kolitz, JE; Larson, M; Louie, AC; Pigneux, A; Recher, C; Rizzeri, DA; Schiller, G; Warzocha, K | 1 |
| Freyer, CW; Gupta, N; Wang, ES; Wetzler, M | 1 |
| Andersson, BS; Champlin, RE; Ji, J; Li, Y; Liu, Y; Murray, D; Popat, U; Valdez, BC | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, MN; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stackelberg, AV; Starý, J; von Neuhoff, C; Zimmermann, M | 1 |
| Bourquin, JP; Creutzig, U; Dworzak, M; Fleischhack, G; Graf, N; Gruhn, B; Klingebiel, T; Kremens, B; Lehrnbecher, T; Reinhardt, D; Stray, J; von Neuhoff, C; von Stackelberg, A; Zimmermann, M | 1 |
| Chen, J; Liu, Y; Shen, Y; Wu, D | 1 |
| Jamy, O; Martin, MG; Wiedower, E | 1 |
| Borg, K; Calbecka, M; Czekalska, S; Ejduk, A; Florek, I; Gadomska, G; Gajkowska-Kulik, J; Giebel, S; Grosicki, S; Haus, O; Holowiecki, J; Jakobczyk, M; Jazwiec, B; Jedrzejczak, WW; Karabin, K; Kata, D; Kielbinski, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Libura, J; Libura, M; Matiakowska, K; Paluszewska, M; Pawelczyk, M; Piatkowska-Jakubas, B; Skotnicki, A; Solarska, I; Warzocha, K; Wierzbowska, A; Zawada, M | 1 |
| Chao, Z; Chen, XM; Deng, CX; DU, X; Huang, X; Lai, PL; Li, MM; Liao, PJ; Ling, W; Lu, ZS; Wan, CC; Wang, YL; Weng, JY; Wu, SJ; Zhong, LY; Zou, XL | 1 |
| Ahmed, N; Baskind, P; Liu, D; Seiter, K; Shaikh, A | 1 |
| Duan, MH; Feng, J; Han, X; Li, J; Tian, LP; Yang, C; Zhang, L; Zhang, M; Zhang, W; Zhang, Y; Zhou, DB | 1 |
| Bang, SM; Kim, I; Koh, Y; Lee, JO; Park, H; Park, S; Yoon, SS; Youk, J | 1 |
| Fridle, C; Manz, MG; Medinger, M; Pabst, T; Passweg, J; Seipel, K; Wilk, MC | 1 |
| Butrym, A; Czemerska, M; Giebel, S; Golos, A; Grosicki, S; Holowiecka-Goral, A; Holowiecki, J; Katarzyna Budziszewska, B; Kloczko, J; Kuliczkowski, K; Kyrcz-Krzemien, S; Lange, A; Madry, K; Mordak-Domagala, M; Piszcz, J; Pluta, A; Razny, M; Robak, T; Sulek, K; Szydlo, R; Warzocha, K; Wawrzyniak, E; Wierzbowska, A; Wiktor-Jedrzejczak, W; Wrzesien-Kus, A; Zwolinska, M | 1 |
| Abboud, C; Becker, M; Friedberg, J; Ifthikharuddin, J; Komrokji, RS; Liesveld, JL; Messina, P; Mulford, D; Oliva, J; Phillips, G; Walker, AR | 1 |
| Adamia, S; Ciccarelli, BT; Ghobrial, IM; Hatjiharissi, E; Hunter, ZR; Ioakimidis, L; Leleu, X; Manning, R; Moreau, AS; Patterson, CJ; Roccaro, A; Sacco, A; Soumerai, J; Treon, SP | 1 |
| Dutka, M; Flont, M; Gawronski, K; Giebel, S; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Konopka, L; Kuliczkowski, K; Lech-Maranda, E; Paluszewska, M; Palynyczko, G; Piatkowska-Jakubas, B; Robak, T; Seweryn, M; Skotnicki, A; Sokolowski, J; Sulek, K; Szpila, T; Warzocha, K; Wegrzyn, J; Zdziarska, B | 1 |
| Abboud, CN; Augustin, K; DiPersio, JF; Hladnik, L; Martin, MG; Welch, JS | 1 |
| Crews, KR; Inaba, H; Pounds, S; Pui, CH; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Stewart, CF; Yang, S | 1 |
| Miller, HJ; Saven, A; Schram, ED; Sigal, DS | 1 |
| Teh, TC; Wei, A | 1 |
| Fernandez, HF; George, TJ; Ho, VQ; Kharfan-Dabaja, MA; Komrokji, RS; Lancet, JE; List, AF; Pinilla-Ibarz, J; Price, SL; Wetzstein, GA | 1 |
| Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Kuliczkowski, K; Kyrcz-Krzemien, S; Piatkowska-Jakubas, B; Robak, T; Skotnicki, AB; Sulek, K; Wach, M; Warzocha, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Adamkiewicz-Drożyńska, E; Bączek, T; Balcerska, A; Belka, M; Konieczna, L; Maciejka-Kapuścińska, L; Niedźwiecki, M; Wachowiak, J; Wiśniewski, J | 1 |
| Bowman, WP; Campana, D; Cao, X; Dahl, G; Inaba, H; Jenkins, L; Pounds, S; Pui, CH; Ribeiro, RC; Rubnitz, JE; Taub, JW | 1 |
| Appelbaum, FR | 1 |
| Behm, FG; Crews, KR; Gandhi, V; Plunkett, W; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Srivastava, DK; Stewart, CF; Tong, X | 1 |
| Dmoszyńska, A; Grosicki, S; Hellmann, A; Hołowiecki, J; Jedrzejczak, W; Kowal, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Lech-Marańda, E; Maj, S; Robak, T; Skotnicki, A; Wierzbowska, A; Wrzesień-Kuś, A | 1 |
| Baran, W; Dmoszynska, A; Giebel, S; Grosicki, S; Haus, O; Hellmann, A; Holowiecki, J; Jagoda, K; Jakubas, B; Jedrzejczak, WW; Kielbinski, M; Kloczko, J; Komarnicki, M; Konopka, L; Kuliczkowski, K; Kyrcz-Krzemien, S; Marianska, B; Paluszewska, M; Pluta, A; Robak, T; Skotnicki, A; Stella-Holowiecka, B; Sulek, K; Wierzbowska, A; Zawilska, K; Zdziarska, B | 1 |
| Hamaki, T; Heike, Y; Hori, A; Imataki, O; Kami, M; Kim, SW; Kishi, Y; Kojima, R; Masuo, S; Miyakoshi, S; Murashige, N; Onishi, Y; Sakiyama, M; Takaue, Y; Taniguchi, S; Tanosaki, R; Tobinai, K | 1 |
| Cortes, J; Faderl, S; Ferrajoli, A; Garcia-Manero, G; Giles, F; Hennessy, B; Kantarjian, H; O'brien, S; Ossa, G; Verstovsek, S | 1 |
| Albertioni, F; Löfgren, C; Paul, C | 1 |
| Gratwohl, A; Rimner, T; Tichelli, A; Went, P | 1 |
| Grosicki, S; Hellmann, A; Holowiecki, J; Jedrzejczak, WW; Kachel, L; Krawczyk-Kulis, M; Marianska, B; Mital, A; Paluszewska, M; Piatkowska-Jakubas, B; Sadus-Wojciechowska, M; Skotnicki, AB; Wach, M; Wojnar, J; Wrzesien-Kus, A | 1 |
| Adema, AD; Albertoni, F; Floor, K; Hubeek, I; Kaspers, GJ; Peters, GJ; Zuurbier, L | 1 |
| Cebula, B; Giebel, S; Grosicki, S; Hołowiecki, J; Kiełbiński, M; Kuliczkowski, K; Kyrcz-Krzemień, S; Kłoczko, J; Piatkowska-Jakubas, B; Pluta, A; Robak, T; Skotnicki, AB; Wawrzyniak, E; Wierzbowska, A; Wrzesień-Kuś, A; Zawilska, K | 1 |
| Góra-Tybor, J; Robak, T | 1 |
| Hansz, J; Kozłowska-Skrzypczak, M; Sawiński, K | 2 |
| Blakley, RL; Crom, WR; Hurwitz, CA; Krance, RA; Luo, X; Mahmoud, H; Ribeiro, R; Roberts, WM; Santana, VM | 1 |
| Fridborg, H; Killander, A; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P; Oberg, G; Simonsson, B | 1 |
| Csoka, K; de la Torre, M; Fridborg, H; Kristensen, J; Larsson, R; Liliemark, J; Nygren, P | 1 |
| Foley, KM; Rosenblum, M; Vahdat, L; Warrell, RP; Wile, MJ; Wong, ET | 1 |
| Chucrallah, A; Estey, E; Gandhi, V; Keating, MJ; Plunkett, W | 1 |
| Andreeff, HM; Beran, M; Estey, E; Gandhi, V; Kantarjian, HM; Koller, CA; Kornblau, SM; O'Brien, S; Plunkett, W | 1 |
| Korycka, A; Robak, T | 1 |
| Delannoy, A; Doyen, C; Ferrant, A; Martiat, P; Michaux, JL; Mineur, P; Van Den Neste, E; Zenebergh, A | 1 |
| Albertioni, F; Eriksson, S; Liliemark, J; Lotfi, K; Månsson, E; Peterson, C; Pettersson, B; Spasokoukotskaja, T | 1 |
| Bennett, JM; Cripe, LD; Gerad, H; Gordon, MS; Longo, W; Mazza, J; Paietta, E; Rowe, JM; Tallman, MS; Young, ML | 1 |
| Behm, FG; Blakley, RL; Crews, KR; Head, DR; Hurwitz, CA; Krance, RA; Mahmoud, H; Raimondi, SC; Ribeiro, RC; Roberts, WM; Srivastava, DK; Tong, X | 1 |
| Behm, FG; Pritchard, M; Pui, CH; Raimondi, SC; Razzouk, BI; Ribeiro, RC; Rubnitz, JE; Sandlund, JT; Srivastava, DK; Tong, X | 1 |
| Kami, M; Kanai, S; Kanda, Y; Kato, K; Kawano, Y; Makimoto, A; Matsubara, H; Mineishi, S; Nakai, K; Ogasawara, T; Ohnishi, T; Saito, T; Shoji, N; Takaue, Y; Tanosaki, R; Tobinai, K; Wakasugi, H | 1 |
| Belt, J; Brenner, MK; Crom, W; Hurwitz, CA; Krance, R; Mahmoud, H; Ribeirio, R; Roberts, WM; Santana, VM; Schell, MJ | 1 |
13 review(s) available for cladribine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Reported Pericardial Toxicities Associated with Acute Myelogenous Leukemia Treatments: A Pharmacovigilance Analysis of the FDA Adverse Reporting Database.
Topics: Adolescent; Adult; Aminopyridines; Anthracyclines; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Decitabine; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Pericarditis; Pharmacovigilance; Sulfonamides; Triazines; United States; United States Food and Drug Administration | 2022 |
Cladribine, cytarabine, and filgrastim based regimen in relapsed or refractory acute myeloid leukemia: A systematic review and meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Remission Induction | 2023 |
The role of cladribine in acute myeloid leukemia: an old drug up to new tricks.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Pharmaceutical Preparations; Remission Induction | 2020 |
Long-term follow-up of Cladribine, high-dose Cytarabine, and Idarubicin as salvage treatment for relapsed acute myeloid leukemia and literature review.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Cladribine; Cytarabine; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Prognosis; Recurrence; Salvage Therapy; Survival Analysis; Treatment Outcome | 2020 |
Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.
Topics: Age Factors; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Arsenic Trioxide; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Core Binding Factors; Cytarabine; Daunorubicin; Gemtuzumab; Humans; Leukemia, Myeloid, Acute; Leukemia, Promyelocytic, Acute; Maintenance Chemotherapy; Mutation; Myelodysplastic Syndromes; Myeloproliferative Disorders; Neoplasm, Residual; Sulfonamides; Survival Rate; Translational Research, Biomedical; Tretinoin; Vidarabine | 2021 |
Allogeneic hematopoietic cell transplantation in morphologic leukemia-free aplastic state.
Topics: Adult; Aged; Allografts; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Filgrastim; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Transplantation Conditioning; Treatment Outcome; Young Adult | 2017 |
Cladribine in the remission induction of adult acute myeloid leukemia: where do we stand?
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Cytarabine; Dose-Response Relationship, Drug; Drug Interactions; Heart Diseases; Hematologic Diseases; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Liposomes; Meta-Analysis as Topic; Mucositis; Multicenter Studies as Topic; Neoplasms, Second Primary; Remission Induction; Survival Rate; Treatment Outcome | 2019 |
Detection of AML-specific mutations in pediatric patient plasma using extracellular vesicle-derived RNA.
Topics: Adult; Animals; Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Humans; Leukemia, Myeloid, Acute; Nucleophosmin; Remission Induction; Survival Rate | 2019 |
Efficacy and toxicity of cladribine for the treatment of refractory acute myeloid leukemia: a meta-analysis.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute | 2019 |
CD56-Positive Acute Myeloid Leukemia Following Treatment of Hairy Cell Leukemia with Cladribine - Report of 2 Cases and Review of the Literature.
Topics: Antineoplastic Agents; CD56 Antigen; Cladribine; Fatal Outcome; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Remission Induction | 2019 |
Revisiting the role of cladribine in acute myeloid leukemia: an improvement on past accomplishments or more old news?
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Cladribine; Clinical Trials as Topic; Humans; Leukemia, Myeloid, Acute; Recurrence; Treatment Outcome | 2015 |
Beyond hairy cell: the activity of cladribine in other hematologic malignancies.
Topics: Antineoplastic Agents; Cladribine; Hematologic Neoplasms; Humans; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Waldenstrom Macroglobulinemia | 2010 |
Management of patients with systemic mastocytosis: review of M. D. Anderson Cancer Center experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cladribine; Combined Modality Therapy; Cytarabine; Female; Humans; Idarubicin; Imatinib Mesylate; Interferon-alpha; Leukemia, Myeloid, Acute; Male; Mastocytosis, Systemic; Middle Aged; Myelodysplastic Syndromes; Piperazines; Prospective Studies; Pyrimidines; Stem Cell Transplantation; Treatment Outcome | 2004 |
33 trial(s) available for cladribine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Cladribine-based debulking chemotherapy sequential with reduced intensity regimen and post-transplantation maintenance for refractory myeloid leukemia: a prospective phase II clinical trial.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Cytoreduction Surgical Procedures; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Prospective Studies; Remission Induction; Transplantation Conditioning | 2022 |
Phase II Study of Venetoclax Added to Cladribine Plus Low-Dose Cytarabine Alternating With 5-Azacitidine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bridged Bicyclo Compounds, Heterocyclic; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged | 2022 |
Results from a phase I study of continuous infusion cladribine, high-dose cytarabine, and mitoxantrone for relapsed/refractory high-grade myeloid neoplasms.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local | 2023 |
Phase 1/2 study of sorafenib added to cladribine, high-dose cytarabine, G-CSF, and mitoxantrone in untreated AML.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Sorafenib | 2023 |
Phase II study of cladribine, idarubicin, and ara-C (CLIA) with or without sorafenib as initial therapy for patients with acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Remission Induction; Sorafenib | 2023 |
Early induction intensification with cladribine, cytarabine, and mitoxantrone (CLAM) in AML patients treated with the DAC induction regimen: a prospective, non-randomized, phase II study of the Polish Adult Leukemia Group (PALG).
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Mitoxantrone; Poland; Prospective Studies; Remission Induction | 2020 |
Selinexor combined with cladribine, cytarabine, and filgrastim in relapsed or refractory acute myeloid leukemia.
Topics: Adult; Aged; Animals; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Filgrastim; Humans; Hydrazines; Leukemia, Myeloid, Acute; Male; Mice, Inbred C57BL; Middle Aged; Remission Induction; Treatment Outcome; Triazoles; Young Adult | 2020 |
Randomized phase 1 study of sequential ("primed") vs. concurrent decitabine in combination with cladribine, cytarabine, G-CSF, and mitoxantrone (CLAG-M) in adults with newly diagnosed or relapsed/refractory acute myeloid leukemia (AML) or other high-grade
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Treatment Outcome | 2020 |
Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials.
Topics: Adolescent; Aminoglycosides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Asparaginase; Child; Child, Preschool; Cladribine; Clinical Protocols; Consolidation Chemotherapy; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Infant; Infant, Newborn; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm, Residual; Recurrence; Retrospective Studies; Survival Analysis; Time Factors; Treatment Outcome; Young Adult | 2017 |
Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study.
Topics: Adenine; Adult; Aged; Antineoplastic Agents; Area Under Curve; Bone Marrow; Bortezomib; Cladribine; Disease-Free Survival; Female; Hematologic Neoplasms; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Microscopy, Fluorescence; Middle Aged; Odds Ratio; Pilot Projects; Piperidines; Positron Emission Tomography Computed Tomography; Pyrazoles; Pyrimidines; Remission Induction; ROC Curve; Young Adult | 2017 |
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Disease-Free Survival; Female; Granulocyte Colony-Stimulating Factor; Hematologic Neoplasms; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Survival Rate | 2019 |
Phase I study of cladribine, cytarabine, granulocyte colony stimulating factor (CLAG regimen) and midostaurin and all-trans retinoic acid in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; fms-Like Tyrosine Kinase 3; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mutation; Nuclear Proteins; Nucleophosmin; Recurrence; Remission Induction; Staurosporine; Treatment Outcome; Tretinoin | 2014 |
Phase II, multicenter, randomized trial of CPX-351 (cytarabine:daunorubicin) liposome injection versus intensive salvage therapy in adults with first relapse AML.
Topics: Adult; Aged; Aminoglycosides; Amsacrine; Antibodies, Monoclonal, Humanized; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Gemtuzumab; Humans; Injections; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Liposomes; Male; Middle Aged; Mitoxantrone; Recurrence; Remission Induction; Risk Assessment; Salvage Therapy; Treatment Outcome; Vidarabine | 2015 |
Additional treatment with 2-Chloro-2-Deoxyadenosine during consolidation in children with high-risk acute myeloid leukemia does not improve survival.
Topics: Antineoplastic Agents; Child; Child, Preschool; Cladribine; Humans; Leukemia, Myeloid, Acute | 2015 |
Randomised Introduction of 2-CDA as Intensification during Consolidation for Children with High-risk AML--results from Study AML-BFM 2004.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Idarubicin; Infusions, Intravenous; Leukemia, Myeloid, Acute; Prognosis; Survival Rate | 2015 |
Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial.
Topics: Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Induction Chemotherapy; Karyotyping; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Remission Induction | 2017 |
Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Blast Crisis; Bone Marrow; Cladribine; Cytarabine; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Imatinib Mesylate; Leukemia, Myeloid, Acute; Male; Middle Aged; Piperazines; Pyrimidines; Recurrence; Time Factors | 2008 |
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG).
Topics: Adolescent; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Bacteremia; Candida; Cladribine; Cytarabine; Daunorubicin; Female; Fungemia; Gram-Negative Bacteria; Gram-Positive Bacteria; Humans; Incidence; Leukemia, Myeloid, Acute; Male; Middle Aged; Poland; Treatment Outcome; Young Adult | 2010 |
Combination of cladribine plus topotecan for recurrent or refractory pediatric acute myeloid leukemia.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Maximum Tolerated Dose; Recurrence; Retreatment; Topotecan | 2010 |
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Analysis; Vidarabine; Young Adult | 2012 |
Treatment outcome in older patients with childhood acute myeloid leukemia.
Topics: Adolescent; Adult; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Combined Modality Therapy; Cytarabine; Etoposide; Female; Follow-Up Studies; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Prognosis; Survival Rate; Transplantation, Autologous; Young Adult | 2012 |
Interim comparison of a continuous infusion versus a short daily infusion of cytarabine given in combination with cladribine for pediatric acute myeloid leukemia.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Bone Marrow; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Drug Administration Schedule; Etoposide; Female; Humans; Infant; Leukemia, Myeloid, Acute; Male; Remission Induction | 2002 |
A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Disease-Free Survival; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Prognosis; Recurrence; Remission Induction; Survival Rate | 2003 |
Addition of cladribine to daunorubicin and cytarabine increases complete remission rate after a single course of induction treatment in acute myeloid leukemia. Multicenter, phase III study.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Treatment Outcome | 2004 |
Reduced-intensity stem cell transplantation from an HLA-identical sibling donor in patients with myeloid malignancies.
Topics: Adult; Aged; Antilymphocyte Serum; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Busulfan; CD3 Complex; Cladribine; Disease-Free Survival; Feasibility Studies; Female; Graft vs Host Disease; Graft vs Leukemia Effect; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Recurrence; Time Factors; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome; Vidarabine | 2004 |
Therapeutic and neurotoxic effects of 2-chlorodeoxyadenosine in adults with acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Axons; Cladribine; Humans; Infusions, Intravenous; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Motor Neurons; Neural Conduction; Peripheral Nervous System Diseases; Sural Nerve | 1994 |
Chlorodeoxyadenosine and arabinosylcytosine in patients with acute myelogenous leukemia: pharmacokinetic, pharmacodynamic, and molecular interactions.
Topics: Adenosine Triphosphate; Adult; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Base Sequence; Biotransformation; Cladribine; Cytarabine; DNA Replication; DNA, Neoplasm; Humans; Leukemia, Myeloid, Acute; Molecular Sequence Data; Neoplasm Proteins; Neoplastic Stem Cells; Prodrugs; Ribonucleotide Reductases; Salvage Therapy | 1996 |
Clinical and laboratory studies of 2-chlorodeoxyadenosine +/- cytosine arabinoside for relapsed or refractory acute myelogenous leukemia in adults.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Arabinofuranosylcytosine Triphosphate; Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Recurrence | 1996 |
2-Chlorodeoxyadenosine with or without daunorubicin in relapsed or refractory acute myeloid leukemia.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Cladribine; Daunorubicin; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Survival Rate; Treatment Outcome | 1998 |
Phase II trial of 2-chlorodeoxyadenosine in patients with relapsed/refractory acute myeloid leukemia: a study of the Eastern Cooperative Oncology Group (ECOG), E5995.
Topics: Adult; Aged; Antineoplastic Agents; Cladribine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence | 2000 |
Experience with 2-chlorodeoxyadenosine in previously untreated children with newly diagnosed acute myeloid leukemia and myelodysplastic diseases.
Topics: Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Cladribine; Disease-Free Survival; Female; Humans; Infant; Infant, Newborn; Infusions, Intravenous; Leukemia, Myeloid, Acute; Male; Myelodysplastic Syndromes; Treatment Outcome | 2001 |
Therapeutic potential of a reduced-intensity preparative regimen for allogeneic transplantation with cladribine, busulfan, and antithymocyte globulin against advanced/refractory acute leukemia/lymphoma.
Topics: Adolescent; Adult; Aged; Antilymphocyte Serum; Busulfan; Cladribine; Combined Modality Therapy; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Myelodysplastic Syndromes; Pilot Projects; Staphylococcal Infections; Survival Analysis; Transplantation Chimera; Transplantation, Homologous; Treatment Outcome | 2002 |
Current strategies for treatment of acute myeloid leukemia at St Jude Children's Research Hospital.
Topics: 2-Chloroadenosine; Acute Disease; Adolescent; Adult; Amsacrine; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Child; Child, Preschool; Cladribine; Cytarabine; Daunorubicin; Deoxyadenosines; Etoposide; Humans; Infant; Leukemia, Myeloid, Acute; Remission Induction | 1992 |
54 other study(ies) available for cladribine and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
[Clinical outcomes of 31 patients with acute leukemia receiveing modified conditioning regimen incorporating cladribine for autologous hematopoietic stem cell transplantation].
Topics: Cladribine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Transplantation Conditioning; Transplantation, Autologous | 2021 |
[Efficacy and Safety of Cladribine-based Intensified Conditioning Regimen in Hematopoietic Stem Cell Transplantation in Patients with High-Risk Acute Myeloid Leukemia].
Topics: Busulfan; Cladribine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Retrospective Studies; Transplantation Conditioning | 2022 |
Retrospective analysis of three induction chemotherapy regimens in acute myeloid leukemia including CPX-351, cytarabine/daunorubicin with and without the addition of cladribine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
Homoharringtonine combined with cladribine and aclarubicin (HCA) in acute myeloid leukemia: A new regimen of conventional drugs and its mechanism.
Topics: Aclarubicin; Antineoplastic Combined Chemotherapy Protocols; Child; Cladribine; Granulocyte Colony-Stimulating Factor; Homoharringtonine; Humans; Leukemia, Myeloid, Acute; Retrospective Studies | 2022 |
A retrospective study of cladribine and low-dose cytarabine-based regimens for the treatment of chronic myelomonocytic leukemia and secondary acute myeloid leukemia.
Topics: Cladribine; Cytarabine; Humans; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Prospective Studies; Retrospective Studies | 2023 |
Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Topics: Anthracyclines; Antineoplastic Combined Chemotherapy Protocols; Bacterial Infections; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Infections; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Mitoxantrone; Respiratory Tract Infections; Sepsis | 2023 |
Cladribine- and decitabine-containing conditioning regimen has a low post-transplant relapse rate in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome.
Topics: Chronic Disease; Cladribine; Decitabine; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes; Recurrence; Retrospective Studies | 2023 |
Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Topics: Adolescent; Antineoplastic Agents; Child; Child, Preschool; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Infant; Leukemia, Myeloid, Acute; Male; Neoplasm Recurrence, Local; Remission Induction; Retreatment; Retrospective Studies | 2020 |
Improved survival of AML patients by addition of cladribine to standard induction chemotherapy.
Topics: Adult; Cladribine; Disease-Free Survival; Female; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Survival Rate | 2020 |
Tandem Allogeneic Hematopoietic Stem Cell Transplantation for Salvage Treatment of Acute Myeloid Leukemia Refractory to Induction Chemotherapy: A Case Report.
Topics: Adult; Busulfan; Cladribine; Cyclophosphamide; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Melphalan; Mitoxantrone; Salvage Therapy; Transplantation Conditioning | 2020 |
Accuracy of SIE/SIES/GITMO Consensus Criteria for Unfitness to Predict Early Mortality After Intensive Chemotherapy in Adults With AML or Other High-Grade Myeloid Neoplasm.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Consensus; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Italy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myeloproliferative Disorders; Neoplasm Grading; Predictive Value of Tests; Severity of Illness Index; Survival Rate; Young Adult | 2020 |
Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Child; Child, Preschool; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Etoposide; Female; Follow-Up Studies; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Induction Chemotherapy; Infant; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Neoplasm Recurrence, Local; Prognosis; Retrospective Studies; Salvage Therapy; Survival Rate | 2021 |
Cladribine, cytarabine, and GCSF with and without mitoxantrone (CLAG ± M) is highly effective for poor risk acute myeloid leukemia with adverse karyotype and prior hypomethylating therapy.
Topics: Cladribine; Cytarabine; Humans; Karyotype; Leukemia, Myeloid, Acute; Mitoxantrone | 2021 |
Long-term results of low-intensity chemotherapy with clofarabine or cladribine combined with low-dose cytarabine alternating with decitabine in older patients with newly diagnosed acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Clofarabine; Cytarabine; Decitabine; Humans; Leukemia, Myeloid, Acute; Middle Aged; Nucleophosmin; Treatment Outcome | 2021 |
A Comparison of Clofarabine-based (GCLAC) and Cladribine-based (CLAG) Salvage Chemotherapy for Relapsed/Refractory AML.
Topics: Cladribine; Clofarabine; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Retrospective Studies; Salvage Therapy | 2018 |
Evaluating the Impact of the Addition of Cladribine to Standard Acute Myeloid Leukemia Induction Therapy.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Middle Aged; Propensity Score; Remission Induction; Retrospective Studies; Treatment Outcome | 2018 |
Acute myeloid leukemia induction with cladribine: Outcomes by age and leukemia risk.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Humans; Idarubicin; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Remission Induction; Retrospective Studies; Risk; Survival Analysis; Treatment Outcome; Young Adult | 2018 |
Neutropenia caused by hairy cell leukemia in a patient with myelofibrosis secondary to polycythemia vera: a case report.
Topics: Aged; Antineoplastic Agents; Biomarkers, Tumor; Bone Marrow; Cladribine; Disease Progression; Fatal Outcome; Humans; Janus Kinase 2; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Leukopenia; Male; Neutropenia; Oral Ulcer; Polycythemia Vera; Primary Myelofibrosis; Splenomegaly; Thrombocytopenia | 2018 |
Connecting the Dots: A Case of Myeloid Sarcoma.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Biopsy; Bone Marrow; Cladribine; Cytarabine; Fatal Outcome; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Sarcoma, Myeloid | 2018 |
Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Topics: Aclarubicin; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cohort Studies; Cytarabine; Daunorubicin; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Harringtonines; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Vidarabine; Young Adult | 2018 |
Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; China; Cladribine; Cytarabine; Drug Administration Schedule; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Neutropenia; Prognosis; Proportional Hazards Models; Recurrence; Survival Rate; Treatment Outcome | 2019 |
Decitabine plus CLAG chemotherapy as a bridge to haploidentical transplantation in the setting of acute myeloid leukemia relapse after HLA-matched sibling transplantation: a case report.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Decitabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Histocompatibility Testing; HLA Antigens; Humans; Leukemia, Myeloid, Acute; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Siblings; Transplantation, Haploidentical; Treatment Outcome | 2019 |
RRM1 and RRM2 pharmacogenetics: association with phenotypes in HapMap cell lines and acute myeloid leukemia patients.
Topics: Cell Line, Tumor; Cladribine; Cytarabine; Genetic Association Studies; HapMap Project; Humans; Leukemia, Myeloid, Acute; Linkage Disequilibrium; Pharmacogenetics; Polymorphism, Single Nucleotide; Ribonucleoside Diphosphate Reductase; Tumor Suppressor Proteins | 2013 |
Cladribine, cytarabine, filgrastim, and mitoxantrone (CLAG-M) compared to standard induction in acute myeloid leukemia from myelodysplastic syndrome after azanucleoside failure.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Case-Control Studies; Chemotherapy, Adjuvant; Cladribine; Cytarabine; Disease Progression; Drug Resistance, Neoplasm; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins; Treatment Failure; Young Adult | 2014 |
Cladribine in the treatment of acute myeloid leukemia.
Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cladribine; Cytarabine; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Mitoxantrone; Myelodysplastic Syndromes; Recombinant Proteins | 2014 |
Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Topics: Adenine Nucleotides; Antineoplastic Agents; Apoptosis; Arabinonucleosides; Ataxia Telangiectasia Mutated Proteins; Busulfan; Cell Line, Tumor; Cladribine; Clofarabine; Epigenesis, Genetic; Humans; Leukemia, Myeloid, Acute; Membrane Potential, Mitochondrial; Real-Time Polymerase Chain Reaction; Vidarabine | 2015 |
Addition of Cladribine to Idarubicin and Cytarabine during Induction Increases the Overall Efficacy Rate in Adult Patients with Acute Myeloid Leukemia: A Matched-Pair Retrospective Comparison.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Drug Synergism; Female; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Retrospective Studies; Treatment Outcome; Young Adult | 2014 |
Induction of Acute Myeloid Leukemia with Idarubicin, Cytarabine and Cladribine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Female; Follow-Up Studies; Humans; Idarubicin; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasm Staging; Prognosis; Remission Induction; Retrospective Studies; Survival Rate; Young Adult | 2015 |
Cladribine added to daunorubicin-cytarabine induction prolongs survival of FLT3-ITD+ normal karyotype AML patients.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Karyotype; Leukemia, Myeloid, Acute; Treatment Outcome | 2016 |
[Effectiveness of CLAT Protocol for Treating Patients with Refractory Acute Myeloid Leukemia].
Topics: Adolescent; Adult; Agranulocytosis; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Thrombocytopenia; Topotecan; Young Adult | 2016 |
CLAG-based induction therapy in previously untreated high risk acute myeloid leukemia patients.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Granulocyte Colony-Stimulating Factor; Humans; Induction Chemotherapy; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Risk; Survival Rate; Treatment Outcome | 2016 |
[Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Neutropenia; Recurrence; Retrospective Studies; Young Adult | 2016 |
Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Topics: Adult; Aged; Aged, 80 and over; Allografts; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Combined Modality Therapy; Cytarabine; Disease-Free Survival; Drug Evaluation; Drug Resistance, Neoplasm; Female; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Proportional Hazards Models; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Vidarabine | 2016 |
Cladribine, cytarabine and idarubicin (CLA-Ida) salvage chemotherapy in relapsed acute myeloid leukemia (AML).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Hematopoietic Stem Cell Transplantation; Humans; Idarubicin; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Remission Induction; Salvage Therapy; Transplantation, Homologous; Treatment Outcome; Young Adult | 2017 |
Increased incidence of transformation and myelodysplasia/acute leukemia in patients with Waldenström macroglobulinemia treated with nucleoside analogs.
Topics: Adult; Aged; Aged, 80 and over; Cell Transformation, Neoplastic; Chlorambucil; Cladribine; Female; Follow-Up Studies; Humans; Incidence; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Male; Middle Aged; Myelodysplastic Syndromes; Nucleosides; Retrospective Studies; Vidarabine; Waldenstrom Macroglobulinemia | 2009 |
Cladribine in the treatment of acute myeloid leukemia: a single-institution experience.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Female; Humans; Injections, Subcutaneous; Leukemia, Myeloid, Acute; Male; Middle Aged; Recurrence; Retrospective Studies; Salvage Therapy; Treatment Outcome; Young Adult | 2009 |
Salvaging AML with CLAG: novel option, or more of the same?
Topics: Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Salvage Therapy; Survival Rate; Treatment Outcome | 2011 |
Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Etoposide; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Neoplasm Recurrence, Local; Remission Induction; Retrospective Studies; Salvage Therapy; Survival Rate; Treatment Outcome; Young Adult | 2011 |
Topotecan exposure estimation in pediatric acute myeloid leukemia supported by LC-MS-based drug monitoring and pharmacokinetic analysis.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Calibration; Chromatography, Liquid; Chromatography, Reverse-Phase; Cladribine; Drug Dosage Calculations; Drug Monitoring; Female; Half-Life; Humans; Leukemia, Myeloid, Acute; Limit of Detection; Linear Models; Metabolic Clearance Rate; Recurrence; Reference Standards; Reproducibility of Results; Spectrometry, Mass, Electrospray Ionization; Topoisomerase I Inhibitors; Topotecan | 2012 |
Haematological cancer: The rule of three in AML induction--is cladribine the answer?
Topics: Antineoplastic Agents; Cladribine; Clinical Trials, Phase III as Topic; Humans; Leukemia, Myeloid, Acute; Randomized Controlled Trials as Topic; Remission Induction | 2012 |
High activity and incomplete cross resistance of nucleoside analogues cladribine and fludarabine versus Ara-C on leukemic cells from patients with AML.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Cladribine; Cytarabine; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Vidarabine | 2005 |
Concomitant hairy cell and acute myeloid leukemia.
Topics: Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Daunorubicin; Genetic Predisposition to Disease; Humans; Leukemia, Hairy Cell; Leukemia, Myeloid, Acute; Male; Middle Aged; Neoplasms, Second Primary; Recurrence; Stem Cell Transplantation | 2006 |
Addition of cladribine to induction/consolidation regimen does not impair peripheral blood stem cell mobilization and bone marrow harvest for autotransplantation in acute myeloid leukemia patients.
Topics: Adolescent; Adult; Antigens, CD34; Bone Marrow Transplantation; Cladribine; Drug Therapy, Combination; Hematopoietic Stem Cell Mobilization; Hematopoietic Stem Cell Transplantation; Humans; Immunosuppressive Agents; Leukemia, Myeloid, Acute; Middle Aged; Tissue and Organ Harvesting; Transplantation Conditioning; Transplantation, Autologous | 2005 |
Cellular resistance against troxacitabine in human cell lines and pediatric patient acute myeloid leukemia blast cells.
Topics: Antineoplastic Agents; Catalysis; Cell Line, Tumor; Cladribine; Cytosine; Deoxycytidine; Dioxolanes; Drug Resistance, Neoplasm; Gemcitabine; HeLa Cells; HL-60 Cells; Humans; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Models, Chemical; Nucleosides | 2006 |
Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukem
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Cladribine; Cytarabine; Female; Granulocyte Colony-Stimulating Factor; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Multivariate Analysis; Odds Ratio; Poland; Recurrence; Salvage Therapy; Stem Cell Transplantation; Treatment Outcome | 2008 |
The influence of 2-chlorodeoxyadenosine (2-CdA) alone and in combination with cyclophosphamide or methotrexate on normal and leukemic hematopoiesis.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Bone Marrow; Cladribine; Cyclophosphamide; Hematopoiesis; Humans; Leukemia L1210; Leukemia P388; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Mice | 1994 |
[Cytokines modify 2-chlorodeoxyadenosine (2-CdA) toxicity in acute myeloid leukemia clonogenic cells (L-CFU)].
Topics: Cell Division; Cladribine; Clone Cells; Growth Substances; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1995 |
Complete hematologic remissions induced by 2-chlorodeoxyadenosine in children with newly diagnosed acute myeloid leukemia.
Topics: Adolescent; Blast Crisis; Child; Child, Preschool; Cladribine; Female; Humans; Infant; Infusions, Intravenous; Karyotyping; Leukemia, Myeloid, Acute; Male | 1994 |
Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amsacrine; Antineoplastic Agents; Cladribine; Cytarabine; Daunorubicin; Drug Interactions; Drug Screening Assays, Antitumor; Drug Synergism; Etoposide; Female; Fluoresceins; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Mitoxantrone; Tumor Cells, Cultured | 1994 |
In vitro activity of 2-chlorodeoxyadenosine (CdA) in primary cultures of human haematological and solid tumours.
Topics: Adrenocortical Carcinoma; Breast Neoplasms; Cladribine; Dose-Response Relationship, Drug; Drug Resistance; Drug Screening Assays, Antitumor; Female; Humans; Kidney Neoplasms; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Lung Neoplasms; Neoplasms; Ovarian Neoplasms; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured | 1994 |
[Effect of 2-chlorodeoxyadenosine, arabinoside cytosine and doxorubicin on acute myeloid leukemia clonogenic cell proliferation].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Division; Cladribine; Cytarabine; Doxorubicin; Humans; Leukemia, Myeloid, Acute; Tumor Cells, Cultured | 1995 |
Interaction of 2-chlorodeoxyadenosine in combination either with interferons or recombinant human tumor necrosis factor alpha on myeloid progenitor cells in vitro.
Topics: Adult; Aged; Antimetabolites, Antineoplastic; Cell Division; Cladribine; Drug Synergism; Growth Inhibitors; Hematopoietic Stem Cells; Humans; Interferon alpha-2; Interferon-alpha; Interferon-gamma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Leukemia, Myeloid, Acute; Middle Aged; Neoplastic Stem Cells; Recombinant Proteins; Tumor Cells, Cultured; Tumor Necrosis Factor-alpha | 1996 |
Biochemical pharmacology and resistance to 2-chloro-2'-arabino-fluoro-2'-deoxyadenosine, a novel analogue of cladribine in human leukemic cells.
Topics: Adenine Nucleotides; Antineoplastic Agents; Arabinonucleosides; Cladribine; Clofarabine; Deoxycytidine Kinase; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; HL-60 Cells; Humans; Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Myeloid, Acute; Leukemia, T-Cell; Phosphorylation; Recombinant Proteins; Tumor Cells, Cultured | 1999 |
Impact of treatment on the outcome of acute myeloid leukemia with inversion 16: a single institution's experience.
Topics: Acute Disease; Adolescent; Antineoplastic Agents; Bone Marrow Transplantation; Child; Child, Preschool; Chromosome Inversion; Chromosomes, Human, Pair 16; Cladribine; Combined Modality Therapy; Cytarabine; Drug Therapy, Combination; Etoposide; Female; Humans; Infant; Leukemia, Megakaryoblastic, Acute; Leukemia, Monocytic, Acute; Leukemia, Myeloid; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Acute; Male; Prognosis; Treatment Outcome | 2001 |